Summary:

Summary

Summary: The upcoming readout from ETNB includes Phase 2b data from the pegozafermin trial in NASH. This is a Suspected Mover for Q1...

Summary

(Posted 10am CST) $XBI $81.76 | -3.16% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...

(Posted 10am CST) $XBI $81.76 | -3.16% Table of Contents: Top 10 AM Positive Movers Top 10 AM Negative Movers Top 10 AM Volume Movers...